PLX
Protalix BioTherapeutics, Inc.Company Information
- Company Name
- Protalix BioTherapeutics, Inc.
- CIK
- CIK0001006281
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- PLX: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- PLX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-19
- Last sale
- 2025-11-18
- Shares purchased (TTM)
- 185,000
- Shares sold (TTM)
- 168
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,576,553
- Shares outstanding
- 79,986,325
- Ownership
- 18.22%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 1.91%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 27 | 41 | 15 | 14 | 18 | 19 | 20 | 27 | 23 | 27 | 24 | 20 | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | 1 | 1 | 1 | - | - | - | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 17 | 3 | 9 | 14 | 9 | 5 | 3 | 2 | 10 | 4 | 5 | 9 | ||||||
| Other Assets Current | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Inventory Net | 32 | 30 | 26 | 21 | 21 | 20 | 21 | 17 | 21 | 22 | 19 | 22 | ||||||
| Assets Current | 92 | 86 | 67 | 67 | 65 | 61 | 60 | 48 | 77 | 75 | 70 | 73 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Defined Benefit Plan Assets For Plan Benefits Noncurrent | - | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Government Assistance Amount Cumulative Noncurrent | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Deferred Income Tax Assets Net | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Operating Lease Right Of Use Asset | 8 | 8 | 8 | 8 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | ||||||
| Assets | 110 | 102 | 82 | 82 | 78 | 74 | 73 | 62 | 92 | 90 | 84 | 88 | ||||||
Accounts Payable And Accrued Liabilities Current | ||||||||||||||||||
| Accounts Payable Trade Current | 7 | 4 | 5 | 5 | 7 | 4 | 5 | 3 | 4 | 3 | 4 | 3 | ||||||
| Accounts Payable Other Current | - | - | - | - | - | - | - | 20 | 19 | 19 | 20 | 19 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 0 | - | 20 | 20 | 20 | 20 | ||||||
| Operating Lease Liability Current | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | 13 | 11 | 0 | - | ||||||
| Liabilities Current | 31 | 27 | 27 | 22 | 24 | 24 | 26 | 24 | 58 | 55 | 46 | 43 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 8 | 7 | 7 | 7 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | ||||||
| Liabilities Noncurrent | 8 | 8 | 8 | 7 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | ||||||
| Liabilities | 39 | 35 | 34 | 29 | 29 | 29 | 30 | 29 | 63 | 60 | 51 | 49 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Additional Paid In Capital Common Stock | - | - | 433 | - | - | - | 422 | - | - | - | 415 | - | ||||||
| Retained Earnings Accumulated Deficit | - | - | -385 | - | - | - | -378 | - | - | - | -382 | - | ||||||
| Stockholders Equity | 71 | 67 | 48 | 53 | 50 | 45 | 43 | 32 | 29 | 30 | 34 | 38 | ||||||
| Liabilities And Stockholders Equity | 110 | 102 | 82 | 82 | 78 | 74 | 73 | 62 | 92 | 90 | 84 | 88 | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 185 | - | - | - | 185 | - | - | - | 185 | - | ||||||
| Common Stock Shares Issued | - | - | 80 | - | - | - | 76 | - | - | - | 73 | - | ||||||
| Shares Outstanding | - | - | 80 | - | - | - | 76 | - | - | - | 73 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialProtalix BioTherapeutics, Inc. (PLX) — SEC Financial Statements & Analysis
Protalix BioTherapeutics, Inc. (PLX) is a biological products, (no diagnostic substances) company, incorporated in DE. Protalix BioTherapeutics, Inc. trades on NYSE as: PLX. Protalix BioTherapeutics, Inc. (PLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Protalix BioTherapeutics, Inc. carries a market cap of $186.37M, a P/E ratio of 9.84x, a P/B ratio of 2.61x, a P/S ratio of 2.31x, an enterprise value of $158.95M, and an EV/EBITDA multiple of 6.39x. On profitability, it posts a gross margin of 130.80%, an operating margin of 28.89%, a net margin of 23.50%, a Return on Equity (ROE) of 31.23%, a Return on Assets (ROA) of 20.07%, and a Return on Invested Capital (ROIC) of 53.29%. Per share, it reports EPS of $0.24, diluted EPS of $0.23, free cash flow per share of $0.10, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 30.14% year-over-year, net income growth of 201.91% year-over-year, and EPS growth of 196.92% year-over-year. On the balance sheet, it maintains a current ratio of 2.94x, a quick ratio of 1.91x, working capital of $60.83M, a debt-to-equity ratio of 0.55x, a debt ratio of 0.35, free cash flow of $7.67M (TTM), and net debt of $-27.42M. Figures sourced from SEC EDGAR.
- Market Cap
- $186.37M
- P/E TTM
- 9.84x
- EPS TTM
- $0.24
- P/B TTM
- 2.61x
- ROE TTM
- 31.23%
- ROA TTM
- 20.07%
- Debt To Equity
- 0.55x
- Free Cash Flow TTM
- $7.67M
- Net Revenue TTM Growth 1Y
- 30.14%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Protalix BioTherapeutics, Inc. in?
Protalix BioTherapeutics, Inc. (PLX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does PLX trade on?
Protalix BioTherapeutics, Inc. (PLX) trades on the NYSE.
Where is Protalix BioTherapeutics, Inc. incorporated?
Protalix BioTherapeutics, Inc. is incorporated in DE.
When was Protalix BioTherapeutics, Inc. (PLX)'s most recent SEC filing?
Protalix BioTherapeutics, Inc. (PLX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is PLX's market cap?
Protalix BioTherapeutics, Inc. (PLX) has a market capitalization of $186.37M as of 2026-06-30.
What is PLX's P/E ratio?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month P/E ratio is 9.84x as of 2026-06-30.
What is PLX's EPS (earnings per share)?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month EPS is $0.24 as of 2026-06-30.
What is PLX's ROE (return on equity)?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month Return on Equity (ROE) is 31.23% as of 2026-06-30.
What is PLX's ROA (return on assets)?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month Return on Assets (ROA) is 20.07% as of 2026-06-30.
What is PLX's ROIC (return on invested capital)?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month Return on Invested Capital (ROIC) is 53.29% as of 2026-06-30.
What is PLX's EV/EBITDA?
Protalix BioTherapeutics, Inc. (PLX)'s trailing twelve month EV/EBITDA is 6.39x as of 2026-06-30.